^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Proleukin (aldesleukin)

    i
    Other names: rIL-2, recombinant human interleukin-2, 125-L-Serine-2-133-interleukin 2, r-serHuIL-2
    Company:
    Clinigen, Iovance Biotherap, Novartis
    Drug class:
    IL-2 stimulant, CD122 agonist
    Related drugs:
    2d
    Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer (clinicaltrials.gov)
    P1/2, N=47, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Feb 2026 --> Feb 2027
    Trial completion date
    |
    mTOR (Mechanistic target of rapamycin kinase)
    |
    Jingzhuda (entinostat) • Proleukin (aldesleukin)
    2d
    Isotretinoin With or Without Dinutuximab, Aldesleukin, and Sargramostim Following Stem Cell Transplant in Treating Patients With Neuroblastoma (clinicaltrials.gov)
    P3, N=1449, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
    Trial completion
    |
    Proleukin (aldesleukin) • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
    4d
    RIOT 4B: Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary Tumors (clinicaltrials.gov)
    P1, N=10, Not yet recruiting, Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
    New P1 trial • First-in-human
    |
    Proleukin (aldesleukin)
    11d
    CheckCell-2: CISH Inactivated TILs in the Treatment of NSCLC (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Intima Bioscience, Inc. | N=70 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    PD-L1 negative
    |
    Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Undisclosed CISH inactivated TIL
    11d
    2019LS002: A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering (clinicaltrials.gov)
    P1/2, N=23, Completed, Intima Bioscience, Inc. | Trial primary completion date: Jan 2026 --> May 2025 | Active, not recruiting --> Completed
    Trial completion • Trial primary completion date
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Undisclosed CISH inactivated TIL
    14d
    A Phase II Trial of Low-Dose Interleukin-2 (IL-2) Added to Extra-Corporeal Photopheresis for Steroid-Refractory cGVHD (clinicaltrials.gov)
    P2, N=25, Completed, Dana-Farber Cancer Institute | Active, not recruiting --> Completed | Trial completion date: Dec 2025 --> Sep 2025
    Trial completion • Trial completion date
    |
    IL2 (Interleukin 2)
    |
    Proleukin (aldesleukin)
    17d
    A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study (2025-522427-10-00)
    P1/2, N=10, Not yet recruiting, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
    New P1/2 trial
    |
    LDH elevation
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin)
    17d
    IOV-MEL-202: A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma (2025-522054-40-00)
    P1/2, N=69, Not yet recruiting, Iovance Biotherapeutics Inc.
    New P1/2 trial
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • Amtagvi (lifileucel)
    30d
    A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. (clinicaltrials.gov)
    P1/2, N=24, Not yet recruiting, University of Chicago
    New P1/2 trial
    |
    PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ER (Estrogen receptor) • ALK (Anaplastic lymphoma kinase) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 positive • ER positive • EGFR mutation • BRAF mutation • HER-2 negative • ER positive + HER-2 negative • HER-2 negative + ER positive
    |
    cyclophosphamide • decitabine • Proleukin (aldesleukin)
    1m
    IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients (clinicaltrials.gov)
    P2, N=29, Recruiting, H. Lee Moffitt Cancer Center and Research Institute | Trial primary completion date: Mar 2026 --> Jul 2026
    Trial primary completion date
    |
    BRAF (B-raf proto-oncogene)
    |
    BRAF mutation • BRAF V600
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • Proleukin (aldesleukin)
    1m
    Gene Therapy Using Anti-CEA Cells to Treat Metastatic Cancer (clinicaltrials.gov)
    P1, N=3, Terminated, National Cancer Institute (NCI) | Phase classification: P1/2 --> P1
    Phase classification
    |
    CEACAM5 (CEA Cell Adhesion Molecule 5)
    |
    Proleukin (aldesleukin)
    2ms
    A2-ESO-1 TCR-Engineered T Cells for Relapsed/Refractory Advanced or Metastatic NY-ESO-1 Overexpression Positive Triple Negative Breast Cancer (clinicaltrials.gov)
    P1, N=20, Suspended, University of Southern California | Recruiting --> Suspended
    Trial suspension • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • ER (Estrogen receptor) • PGR (Progesterone receptor) • CTAG1B (Cancer/testis antigen 1B)
    |
    HER-2 negative
    |
    cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • NY-ESO-1 TCR